Objective The validated EORTC quality of life (QOL) questionnaire QLQ-BN20 is a cancer subtype-specific supplement to the QLQ-C30 general QOL questionnaire for patients with primary brain neoplasms. The QLQ-C15-PAL core palliative questionnaire is an abbreviated version of the QLQ-C30 designed to decrease patient burden. We conducted content validation of the QLQ-BN20+2 for patients with brain metastases. Methods and materials Patients undergoing treatment for brain metastases, along with health care professionals (HCPs) completed the QLQ-C15-PAL and QLQ-BN20+2 questionnaires. A structured interview followed to assess for any difficulties with the QLQ-BN20+2, irrelevant items, and whether additional pertinent items should be included. Results Seventy-four patients and 71 HCPs participated. The majority of patients (84 %) were treated with whole-brain radiotherapy only. Over 50 % of patients felt that seizures, hair loss and trouble controlling bladder were not related to brain metastases. Questions regarding uncertainty about the future were the most difficult, although still a small proportion (12-16 %). All items were endorsed by over 50 % of HCPs as 'quite' or 'very' relevant to brain metastases patients, with two exceptions: 15 and 12 % of HCPs rated pruritis and future uncertainty as irrelevant, respectively. Conclusion We report the first content validation of the QLQ-BN20+2 and QLQ-C15-PAL QOL questionnaires for patients undergoing treatment for brain metastases, demonstrating feasibility and relevance. These questionnaires should be used together as universal QOL assessment tools in this setting.
Introduction
Brain metastases are a cause of significant morbidity [1] and are a frequent complication of primary neoplasms such as lung, with over 50 % of patients eventually developing spread to the central nervous system [2] . Improvements in the sensitivity of imaging modalities along with more frequent screening may result in the earlier diagnosis of smaller and/or fewer brain metastases. Overall, the incidence of brain metastases is increasing [3] leading to a greater number of patients undergoing various treatments.
Potential neurological symptoms arising from brain metastases include headache, focal weakness, mental disturbances and ataxia. Additionally, nearly 65 % of patients display some form of cognitive impairment [4, 5] . Symptoms may also arise from the treatment of brain metastases.
Whole-brain radiotherapy (WBRT) has long been the standard approach, with the aim of alleviating or reducing neurological symptoms and decreasing the need for long-term corticosteroids. Treatment options have evolved over the past few decades to include more aggressive approaches such as stereotactic radiosurgery or surgical resection and post-operative RT for certain subgroups of patients with favourable performance status [6] . Prognostic indices such as the Graded Prognostic Assessment identify patients who may benefit from more aggressive treatments [7] . However, even the most favourable prognosis group has a median survival of only 11 months versus 2.6 months in the group with worst prognosis [7] . Traditional endpoints such as survival should therefore not be the sole aim of treatment; quality of life (QOL) should also be evaluated [8] .
Quality of life is a subjective, multidimensional construct that consists of physical and psychosocial factors [9] . To address the need for standardized assessment of QOL and symptoms in oncology, the European Organization for Research and Treatment of Cancer (EORTC) developed the quality of life core questionnaire (QLQ-C30) [10] . It is now one of the most frequently used measures of QOL in oncology clinical trials. Cancer subtype-specific QOL questionnaires have also been developed to supplement the general core questionnaire. One of these, the EORTC QLQ-BN20, was developed [11] and validated [12] in patients with primary brain tumours. The 15-question QLQ-C15-PAL core questionnaire was developed to decrease the burden of the longer QLQ-C30 on patients with advanced cancer [13] .
Studies of patients with brain metastases continue to use the lengthy QLQ-C30 along with the QLQ-BN20 as there is no tool that has been validated specifically for use in this patient population [14] [15] [16] [17] . A previous study assessed QOL in patients with brain metastases prior to and after treatment by administering the QLQ-C15-PAL with the QLQ-BN20+2, a version of the QLQ-BN20 questionnaire with two additional questions to assess cognitive function [18] .
The primary aim of this study was to conduct content validation of the EORTC QLQ-BN20+2 in patients with brain metastases and in health care professionals (HCPs) involved in the care of these patients. 
QLQ-BN20+2 Item
Not at all A little Quite a bit Very much (4) additional issues relevant for the patient, but not included in this questionnaire. A similar procedure was followed by HCPs who were asked to indicate, for each item on the QLQ-BN20+2, its perceived relevance (1 0not at all to 40very much). Relevancy was defined as a combination of the frequency with which a specific complaint occurs, and the degree of difficulty it causes. HCPs were also asked to indicate whether there were irrelevant items, and any additional issues not included in either questionnaire.
Statistical methods
Results were expressed as medians (ranges) for continuous variables as well as proportions for categorical variables. The ranking of most to least important items by HCPs was obtained by the frequency of the top five to ten items that were rated to be included in the QLQ-BN20+2. Figures were created to illustrate both the levels of importance for each item of the QLQ-BN20 +2 and whether it should be included in the final question, for patients and HCP's. All descriptive analyses were performed by Statistical Analysis Software (SAS version 9.2).
Results
A total of 74 patients and 71 health care professionals participated. Demographics are presented in Table 1 . Nearly half of patients had a lung cancer primary (49 %). Median KPS was 70 (range 30-100). At the time of interview, 84 % of patients were undergoing WBRT. Healthcare professions were all from Canada and the majority were radiation therapists (35 %), followed by radiation oncologists (26 %) then nurses (21 %).
Patient responses
Most patients were not bothered at all by seizures (94 %), hair loss (85 %), double vision (84 %), difficulty speaking (82 %) or trouble controlling bladder (73 %; Fig. 1 ). Conversely, many patients were concerned about disruption in family life (80 %), felt unsteady on their feet (79 %) or felt that they had had setbacks in their condition (78 %). Items endorsed as potentially irrelevant (yes/no answer) were seizures (by 84 %), difficulty with bladder control (84 %) and hair loss (64 %; Fig. 2 ). All other items were assessed as being related to their brain metastases by the majority of respondents. Although a small proportion of patients found each of the QLQ-BN20+2 items difficult to answer, there was no single question uniformly identified as upsetting, confusing, or annoying (Appendix I). The items presenting the most issues were: "Did you feel uncertain about the future?" (16 %); "Did you feel you had setbacks in your condition?" (12 %); and "Were you concerned about disruption of family life?" (16 %). However, nearly all stated that they would not change any of the 22 questions.
Only three patients stated that there were irrelevant items on the QLQ-BN20+2. Three sets of repetitive items were described by two patients ("Was your vision blurred?" and "Did you have difficulty reading because of your vision?"; "Did you have trouble with your coordination?" and "Did you feel unsteady on your feet?"; "Did you have trouble finding the right words to express yourself?" and "Did you have trouble communicating your thoughts?"). One patient felt that the question pertaining to hair loss was irrelevant to those not receiving WBRT.
Health care professional responses
Over 50 % of HCPs described each QLQ-BN20+2 item as 'quite' or 'very relevant' except for 'outlook on the future worsened', and 'bothered by itching of skin' (Fig. 3) . In terms of which items were least relevant, over 50 % suggested that 'setbacks in condition', 'outlook on the future worsened', and 'bothered by itching of skin' should be removed (Fig. 4) .
HCPs' detailed responses to each question are summarized in Appendix II. For the future uncertainty items mentioned above that were suggested to be removed, most comments were that HCPs were "not sure why these questions were specific to brain metastases versus any palliative patient" (n08), and that these questions were "too subjective and situational dependent" (n03). Many HCPs also stated that the item pertaining to itching of the skin is "of minimal importance and is easy to treat" (n011). Additionally, there were questions deemed irrelevant because it had been The overall ranking of the most to least important items is in Table 2 . The main items to be definitely included in the final questionnaire pertained to physical symptoms such as seizures, headaches, weakness and difficulty speaking. Finally, 28 (40 %) HCPs described additional items that should be included. These nine common themes were: burden and impact on family and children; other physical and psychological side effects from treatment and disease; understanding prognosis; coping with stress/support system; financial hardship; language issues; independence/carrying out usual activities; intimacy/sex; and perception of whether their QOL is actually being impacted (Appendix III). Burden on family, coping with stress/support systems and independence were the most commonly listed additional issues.
Discussion
To the best of our knowledge, this is the first study to conduct content validation of the EORTC QLQ-BN20+2 for use in brain metastases patients, for which there is currently no widely accepted tool. A review of 14 brain metastases RT trials which evaluated QOL demonstrated a total of 23 different instruments used [20] .
While the QLQ-BN20 has become one of the most commonly used QOL tools in brain metastases studies, along with the Functional Assessment of Cancer Therapy Brain subscale [21] , a recent review of 13 studies using the QLQ-BN20 and QLQ-C30 reveals challenges with compliance and attrition at follow-up assessments [22] . The QLQ-BN20 has been used to assess QOL in lung cancer patients undergoing prophylactic cranial irradiation [23] . Conducting content validation aims to demonstrate the subjective validity of the questionnaire, as primary brain tumour patients may present with slightly different issues than brain metastases patients. The use of the EORTC QLQ-BN20+2 with the QLQ-C15-PAL to assess QOL was first reported in 108 patients undergoing various treatments for brain metastases [19] . The questionnaires showed maintenance (no deterioration) of QOL and improvement in a few QOL scores, which was echoed by a study that used the QLQ-BN20 with the QLQ-C15-PAL to reduce patient burden [14] . It was suggested that these two questionnaires replace the use of the QLQ-BN20 and QLQ-C30 combination previously used in many brain metastases studies in order to decrease attrition rates. Future uncertainty was the most prominent symptom at baseline for these two studies. Our results also concurred with those results, with 77-79 % of patients reporting some level of future uncertainty. Validation of the QLQ-BN20+2 will facilitate comparison of QOL outcomes between trials using this tool.
For all 22 items on the QLQ-BN20+2, there were only three items (seizures, hair loss and incontinence) in which the majority of patients stated the issue was not related to their brain metastases. It is possible that patients rated 'seizure' as unrelated because they had not experienced a seizure. This is in contrast with HCP responses, as seizures were ranked the most important item to be included on the final questionnaire.
As in any QOL questionnaire that assesses psychological and physical symptoms, it is expected that some questions may be difficult to answer, upsetting, confusing, or annoying depending on the patient. There were a small number of patients with such reactions to each of the 22 items. The three items that assessed future uncertainty were the most difficult; however, only two patients stated that these questions should be removed. Many HCPs also rated two future uncertainty items as not being specific to this patient population.
Patients and HCPs had similar opinions in items perceived as irrelevant because they had been addressed in another question. HCPs felt that pruritus was of low priority for inclusion because it is of minimal importance and easy to treat, which is in accordance with the overall ranking of all 22 items. Only three patients stated items should be included: family life, alternative therapy options and satisfaction with information received. More HCPs (40 %) stated that there were additional issues not covered.
The current study is limited in that the structured interview may have been cumbersome for patients to complete, and therefore patients may have been too tired to provide complete input on irrelevant items or additional important issues that may be missing. Furthermore, as cognitively impaired patients were ineligible for this study, our results may be more applicable to patients who have relatively better functioning. The therapeutic benefits of various treatment options for patients with brain metastases are beginning to be supplemented with more QOL research.
Conclusion
The limited consensus on the method of QOL endpoint measurement in clinical trials of patients with brain metastases is a significant barrier to the identification of the most effective treatment option. As we have demonstrated, content validation of the EORTC QLQ-BN20+2 when used concurrently with the EORTC QLQ-C15-PAL for patients with brain metastases, these two QOL tools should be used in future clinical trials involving these patients. 14 Have you had difficulty in concentrating on things, like reading a newspaper or watching television?
• Difficult to answer (n01), usually too weak or exhausted to concentrate (n02) • Upsetting (n01) • Annoying (n01) • Confusing (n01) 15 Have you had difficulty remembering things?
• Related to old age (n02); "I don't know whether it's related to brain metastases" (n02) • Not related to brain metastases (n01) • Upsetting (n01) • Confusing (n01) 16 Did you feel drowsy during the daytime?
• Not related (n02), Not likely related to brain metastases (n01)
• Due to dexamethasone (n01), due to medications and condition (n02) • Confusing (n02)-confused about the term "drowsy" (n01)
• Would not have asked question (n01) 17 Did you have trouble with your coordination?
• Difficult to answer (n02)
• Confusing (n02)-confused about the tern "coordination" (n01)
• Upsetting (n01)
• Due to chemotherapy (n01)
18 Did hair loss bother you?
• Related to chemotherapy and brain metastases (n01)
• Confusing (n02)
• Question did not apply to me because I did not have radiation (n01)
• Would not have asked question (n02) 19 Did itching of the skin bother you?
• Related to chemotherapy (n01)
• Not related (n01)
• Would not have asked question (n01)
20 Did you have weakness of both legs?
• Not related to brain metastases (n03)
• Upsetting (n02)
21 Did you feel unsteady on your feet?
• Related to bone metastases as well (n01)
22 Did you have trouble controlling your bladder?
• Not related (n03)
• Not sure if related to brain metastases (n01)
• Difficult to answer (n01)
